News

The multinational, prospective, randomized, double-blind study will evaluate the effectiveness of AMR101 in reducing the prevalence of first major cardiovascular events in a high-risk patient population. Amarin chairman

The facility, Unit-VI, has been granted approval for Cefotaxime sodium for injection, Ceftriaxone sodium for injection and Cefuroxime sodium for injection, indiainfoline.com reported. Following the approval, the company

The deal is believed to enforce VistaGen’s stem cell technology-based drug rescue activities using Synterys’ medicinal chemistry expertise. VistaGen’s drug rescue initiatives comprise its human pluripotent stem cell

Pertuzumab, a humanised monoclonal antibody, acts by inhibiting the binding of HER2 receptor from other HER receptors, resulting in suppression of cancer cell growth or lead to the

According to the company, the patent will provide exclusivity for Pulmaquin until 22 October 2027. Pulmaquin is a dual release formulation that is a mixture of a liposomal

Melt Extrusion and Calendering Line will help pharmaceutical manufacturers procure extrusion, calendering and cooling equipment from one supplier, packagingeurope.com reported. Melt extrusion, which is a method for drug

The approval allows the company to use VibeX with its KXL system for treating corneal ectasia. Avedro CEO David Muller said this second orphan drug designation and the

The launch follows a settlement with Teva Women’s Health. The global marketing research company for the pharmaceutical industry, IMS Health said Watson is the first applicant to submit

BOLERO-2 (Breast cancer trials of OraL EveROlimus-2), a Phase III, randomized, double-blind, placebo-controlled, multicenter study was devised to assess the safety and efficacy of everolimus in combination with